Clinical Trial

CAR-T Cell Therapy in RelApsed/Refractory Myeloma With ExtrameduLlary Disease - an in Vivo Imaging and Molecular Monitoring Study

Study acronym: CARAMEL
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This clinical trial will investigate the in vivo trafficking of cilta-cel in extramedullary myeloma using 64Cu Super Paramagnetic Iron Oxide Nanoparticle (64Cu SPION) and Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI)
Protocol Amendment History 2 changes
critical Enrollment closed, study ongoing 2026-07-29
notable Primary completion pushed: 2026-01 -> 2027-01 2026-07-29
Trial Details
NCT Number NCT05666700
Lead Sponsor Peter MacCallum Cancer Centre, Australia
Collaborators: Janssen, LP
Conditions Extramedullary Myeloma
Enrollment 10 participants
Start Date 2023-12-08
Primary Completion 2027-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-28